Last reviewed · How we verify
PRAVASTATIN
At a glance
| Generic name | PRAVASTATIN |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
Common side effects
- Musculoskeletal pain
- Nausea/Vomiting
- Upper respiratory infection
- Diarrhea
- Headache
- Hepatic transaminase elevations
- Anxiety/Depression
- Dizziness
- Increased ALT
- Increased AST
- Increased CK
- Eosinophilia
Serious adverse events
- CK elevation >10 times ULN
- Anemia
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Novel Treatment of Radiation Associated Dysphagia With Statins (PHASE2)
- Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) (PHASE2)
- Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE) (PHASE2)
- Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma (PHASE3)
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (PHASE1, PHASE2)
- Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) (PHASE2)
- Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy (PHASE1, PHASE2)
- IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |